ResearcherShenyang Pharmaceutical UniversityActive in the last 2 years
Juanping Zhao
Matched on OpenAlex author ID A5087411164.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Collaborators
- 4
2022: 1 paper · 2023: 1 paper · 2024: 1 paper
Papers 3
- Riboflavin protects against pancreatic cancer metastasis by targeting TGF-β receptor 1. First author DOI 10.1016/j.bioorg.2024.107274↗
- Design and synthesis of dual cathepsin L and S inhibitors and antimetastatic activity evaluation in pancreatic cancer cells. Co-author DOI 10.1016/j.bmcl.2022.129087↗
- ASPER-29 suppresses the metastasis of pancreatic cancer cells by dual inhibition of cathepsin-L and cathepsin-S. Co-author DOI 10.1016/j.cbi.2022.109811↗
Closest collaborators
The 4 strongest of 4 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Enlong Ma · 3 shared papers, 2022–2024
- Paper Riboflavin protects against pancreatic cancer metastasis by targeting TGF-β receptor 1. DOI 10.1016/j.bioorg.2024.107274↗
- Paper Design and synthesis of dual cathepsin L and S inhibitors and antimetastatic activity evaluation in pancreatic cancer c… DOI 10.1016/j.bmcl.2022.129087↗
- Paper ASPER-29 suppresses the metastasis of pancreatic cancer cells by dual inhibition of cathepsin-L and cathepsin-S. DOI 10.1016/j.cbi.2022.109811↗
- Yanchun Li · 2 shared papers, 2022–2024
- Lei Yuan · 2 shared papers, 2022–2023
- Paper Design and synthesis of dual cathepsin L and S inhibitors and antimetastatic activity evaluation in pancreatic cancer c… DOI 10.1016/j.bmcl.2022.129087↗
- Paper ASPER-29 suppresses the metastasis of pancreatic cancer cells by dual inhibition of cathepsin-L and cathepsin-S. DOI 10.1016/j.cbi.2022.109811↗
- Haoqiang Huang · 1 shared paper, 2023
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.